Skip to content
drillr.ai

GH

Guardant Health, Inc.

NASDAQ · USHealthcareMedical - Diagnostics & Research
$148.07-5.00%

Price as of Jul 20, 2026

GH news

Guardant Health, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. UnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening

    UnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening * Updated United policy coverage from the largest commercial insurer in the U.S. means 100 million total covered lives have access to the FDA-approved Shield blood test for colorectal cancer (CRC) screening * Shield is the first and only FDA-approved blood test included in both ACS and NCCN guidelines * With rising rates of CRC in younger people, the first major commercial insurer in the U.S.

    Business Wire ·

  2. Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®

    Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS(®) Blood-based liquid biopsy test enables identification of patients eligible for treatment with HERNEXEOS(®) (zongertinib tablets) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360(®) CDx as a companion diagnostic (CDx) for Boehringer Ingelheim’s HERNEXEOS(®) (zon

    Business Wire ·

  3. Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting

    Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting * New performance data demonstrates validity of Guardant360 Liquid CDx as a comprehensive pan-cancer companion diagnostic * Findings show how Guardant360 Liquid CDx can expand access to targeted therapies by identifying actionable biomarkers missed by genomic testing * Presentations reinforce Guardant

    Business Wire ·

  4. American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

    American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines * Updated ACS guideline offers Shield as a new choice for over 50 million eligible Americans who are not up to date with their colorectal cancer screening * Shield is the first and only FDA-approved blood test included in both ACS and NCCN guidelines Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood te

    Business Wire ·

  5. FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint

    FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint * Guardant Health’s new FDA-approved liquid biopsy integrates genomic and epigenomic insights to provide a more complete, actionable view of cancer from a simple blood draw * Approval strengthens Guardant’s leadership in comprehensive molecular profiling and advances a unified testing experience across liquid and tissue Guardant Health, Inc. (Nasdaq: GH), a leading precision

    Business Wire ·

  6. Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 143,898 shares of its common stock to 267 new non-executive employees with a grant date of May 11, 2026 under the Guardant Health, Inc. 2023 Employment Inducement Incentive A

    Business Wire ·

  7. Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

    Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations * Blood-based test enables identification of patients eligible for targeted treatment with VEPPANU™ * Approval marks Guardant’s third ESR1 companion diagnostic FDA approval to help guide timely treatment decisions for patients with advanced breast cancer Guardant Health, Inc. (Nasdaq: GH)

    Business Wire ·

  8. Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

    Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform * Multi-year global collaboration will leverage Guardant’s tissue and liquid biopsy portfolio to support clinical development and companion diagnostic strategies Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year strategic collab

    Business Wire ·

  9. Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026

    Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2026 after market close on Thursday, May 7, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: w

    Business Wire ·

  10. Gamehost Announces Regular Monthly Dividend for April

    Red Deer, Alberta--(Newsfile Corp. - April 16, 2026) - Gamehost Inc. (TSX: GH) ('Gamehost', the 'Company') Gamehost has declared a cash dividend for the month of April 2026 of $0.05 (CDN) per common share, which equates to $0.60 (CDN) per common share on an annualized basis. The dividend will be paid on May 15, 2026 to shareholders of record on April 30, 2026. This dividend is considered an "Eligible Dividend" and therefore, eligible for the enhanced gross-up and dividend tax credit available

    Newsfile Corp ·

  11. Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan

    Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan * This milestone underscores the power of Guardant Health’s InfinityAI platform and real-world data to enable innovative evidence generation in rare biomarker-defined populations Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that real-world evidence generated from Guardant’s InfinityAI contri

    Business Wire ·

  12. Gamehost Enters into Definitive Agreement to Be Acquired by Pure Casino Entertainment for $13.65 per Share

    Red Deer, Alberta--(Newsfile Corp. - March 30, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost" or the "Corporation") and Pure Casino Entertainment Limited Partnership ("Pure") announced that they have entered into a definitive arrangement agreement (the "Arrangement Agreement") pursuant to which Pure will, indirectly through a subsidiary, acquire all of the issued and outstanding common shares of Gamehost (the "Gamehost Shares") for $13.65 in cash per share (the "Transaction"). Pure operates casinos

    Newsfile Corp ·

  13. Gamehost to Correct Administrative Expense Allocation in Financial Statements; No Impact on Operations or Cash Flow

    Red Deer, Alberta--(Newsfile Corp. - March 18, 2026) - Gamehost Inc. (TSX: GH) The Company has identified an error relating to the treatment under International Financial Reporting Standards ("IFRS") for payments to directors and executive officers in the event of their termination, death, resignation or retirement, or in the event of a change of control of Gamehost. Such payments contained in termination and change of control ("TCoC") agreements were previously disclosed in the Company's manage

    Newsfile Corp ·

  14. Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026

    Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026 * Guardant Reveal demonstrates expanded utility in identifying new, primary cancers during minimal residual disease (MRD) monitoring * Studies show strong performance of Guardant360 Tissue in determining tissue of origin in diagnostically challenging settings Guardant Health, Inc. (Nasdaq: GH), a leading precision oncolog

    Business Wire ·

  15. Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership

    Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership * Partnership marks the first introduction of Shield™ multi-cancer detection test in the region with availability across Hong Kong, Singapore and the Philippines * Eligible Manulife customers in Hong Kong, Singapore and the Philippines will gain access to the Shield MCD test beginning in April 2026 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today

    Business Wire ·

  16. Manulife Announces Exclusive Partnership with Guardant Health to Bring the Shield Multi-Cancer Detection Test to Customers Across Asia

    Manulife Announces Exclusive Partnership with Guardant Health to Bring the Shield Multi-Cancer Detection Test to Customers Across Asia PR Newswire HONG KONG, SINGAPORE, and MANILA, Philippines, March 16, 2026 First insurer in Asia to bring the innovative blood-based multi‑cancer screening solution to Hong Kong, Singapore, and the Philippines TSX/NYSE/PSE: MFC SEHK: 945 HONG KONG, SINGAPORE, and MANILA, Philippines, March 16, 2026 /PRNewswire/ -- Manulife today announced an exclusive partnership

    PR Newswire ·

  17. New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare

    New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare * Survey highlights barriers to colorectal cancer screening for adults 45 and over * Overwhelming majority (92%) of Americans ages 45 and over believe blood-based screening should be covered with no co-pay * Shield™ by Guardant is proven to increase screening rates with a 93% adherence rate by offering a quick, easy option to screen

    Business Wire ·

  18. Gamehost Announces Q4 Financial Results, Retirement, and Dividend for March

    Red Deer, Alberta--(Newsfile Corp. - March 10, 2026) - Gamehost Inc. (TSX: GH) Management and Directors of Gamehost Inc. (the "Company") present results for the twelve and three months ended December 31, 2025 (the "Year" and "Quarter" respectively). Operating revenue for the Quarter was up 4.2% to $22,054,800 ($21,160,000 - 2024). Earnings before interest, taxes, depreciation and amortization ("EBITDA") were up 2.7% to $8,518,500 ($8,295,600 - 2024). EBITDA margin for the Quarter was 38.6% (39.2

    Newsfile Corp ·

  19. Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics

    Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics * Strategic collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest’s vast network * Physicians nationwide now have the ability to order Shield * Shield is proven to increase screening rates with a 93% screening adherence rate Guardant Health, Inc. (Nasdaq: GH), a

    Business Wire ·